PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2006 December; 7(4): E31–E38.
Published online 2014 March 30. doi:  10.1208/pt070487
PMCID: PMC2750324

Industrially feasible alternative approaches in the manufacture of solid dispersions: A technical report

Abstract

The purpose of this report was to compile relevant technical information on various alternative strategies that can be used as feasible approaches in the development of solid dispersions. The technologies discussed in the report are spray coating on sugar beads with a fluidized bed coating system, hot melt extrusion, direct capsule filling, electrostatic spinning, surface active carriers, and supercritical fluid technology. The focus is on basic principles, the equipment involved, and the relevant scale-up work. These technologies have been found to eliminate several drawbacks posed by the conventional methods of manufacturing of solid dispersions such as laborious preparation methods, reproducibility, scaling up of manufacturing processes, stability of drug, and vehicle.

Keywords: hot-melt extrusion, solid dispersions, direct capsule filling, electrostatic spinning, surface-active carriers, supercritical fluid technology

Full Text

The Full Text of this article is available as a PDF (268K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Wadke DA, Serajuddin ATM, Jacobson H. Preformulation testing. In: Lieberman HA, Lachman L, Schwartz JB, editors. Pharmaceutical Dosage Forms: Tablets. New York, NY: Marcel Dekker; 1989. pp. 1–73.
2. Goldberg AH, Gibaldi M, Kanig JL. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. II. Experimental evaluation of eutectic mixture: urea-acetaminophen system. J Pharm Sci. 1966;55:482–487. doi: 10.1002/jps.2600550507. [PubMed] [Cross Ref]
3. Goldberg AH, Gibaldi M, Kanig JL. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures. III. Experimental evaluation of griseofulvin-succinic acid solution. J Pharm Sci. 1966;55:487–492. doi: 10.1002/jps.2600550508. [PubMed] [Cross Ref]
4. Beten DB, Amighi K, Moes AJ. Preparation of controlled-release coevaporates of dipyridamole by loading neutral pellets in a fluidized-bed coating system. Pharm Res. 1995;12:1269–1272. doi: 10.1023/A:1016253119194. [PubMed] [Cross Ref]
5. Ho HO, Shu HL, Tsai T, Sheu MT. The preparation and characterization of solid dispersions on pellets using a fluidized bed system. Int J Pharm. 1996;139:223–229. doi: 10.1016/0378-5173(96)04594-2. [Cross Ref]
6. Gilis PA, De Conde V, Vandecruys R, inventors. Janssen Pharmaceutica NV. Beads having a core coated with an antifungal and a polymer. US patent 5 633 015. May 27, 1997.
7. Kennedy JP, Niebergall PJ. Development and optimization of a solid dispersion hot melt fluid bed coating method. Pharm Dev Technol. 1996;1:51–62. doi: 10.3109/10837459609031418. [PubMed] [Cross Ref]
8. el-Egakey MA, Soliva M, Speise P. Hot extruded dosage forms. Pharm Acta Helv. 1971;46:31–52. [PubMed]
9. Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm. 2002;54:107–117. doi: 10.1016/S0939-6411(02)00061-9. [PubMed] [Cross Ref]
10. Chokshi R, Hossein Z. Hot—Melt Extrusion Technique: A Review. Iran J Pharm Res. 2004;3:3–16.
11. Perissutti B, Newton JM, Podezeck F, Rubessa F. Preparation of extruded Carbamazepine and PEG 4000 as a potential rapid release dosage form. Eur J Pharm Biopharm. 2002;53:125–132. doi: 10.1016/S0939-6411(01)00209-0. [PubMed] [Cross Ref]
12. Hulsmann S, Backensfeld T, Keitel S, Bodmeier R. Melt extrusion—an alternative method for enhancing the dissolution rate of 17β-estradiol hemihydrate. Eur J Pharm Biopharm. 2000;49:237–242. doi: 10.1016/S0939-6411(00)00077-1. [PubMed] [Cross Ref]
13. Zeidler J, Neumann J, Liepold B, Rosenberg J, Berndl G, Vollgraf C, inventors. BASF Actiengesellschaft. Fast-acting analgesic. US patent 6 322 816. November 27, 2001.
14. Verreck G, Baert L, Peeters J, Brewster M. Improving aqueous solubility and bioavailability for itraconazole by solid dispersion approach [Serial online] AAPS PharmSci. 2001;3:M2157–M2157.
15. Verreck G, Six K, Van den Mooter G, Baert L, Peeters J, Brewster ME. Characterization of solid dispersions of itraconazole and hydroxypropylmethyl cellulose prepared by melt extrusion—Part I. Int J Pharm. 2003;251:165–174. doi: 10.1016/S0378-5173(02)00591-4. [PubMed] [Cross Ref]
16. Baert L, Thone D, Verreck G, inventors. Janssen Pharmaceutica. Antifungal compositions with improved bioavailability. World patent 9 744 014. November 27, 1997.
17. Francois D, Jones BE. The hard capsule with the soft center. Paper presented at: European Capsule Technology Symposium; October 11–13, 1978; Constance.
18. Wiley GJ, Ulhah I, Agharkar SN. Development of a semiautomatic system for R&D and clinical use for liquid filled hard gelatin encapsulation. Pharm Technol. 1995;19:72–76.
19. Walker SE, Ganley JA, Bedford K, Eaves T. The filling of molten and thixo formulations into hard gelatin capsules. J Pharm Pharmacol. 1980;32:389–393. doi: 10.1111/j.2042-7158.1980.tb12949.x. [PubMed] [Cross Ref]
20. Serajuddin ATM, Sheen PC, Mufson D, Bernstein DF, Augustine MA. Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersions. J Pharm Sci. 1988;77:414–417. doi: 10.1002/jps.2600770512. [PubMed] [Cross Ref]
21. Serajuddin ATM, Sheen PC, Augustine MA. Improved dissolution of a poorly water-soluble drug from solid dispersions in poly (ethylene glycol): polysorbate 80 mixtures. J Pharm Sci. 1990;79:463–464. doi: 10.1002/jps.2600790524. [PubMed] [Cross Ref]
22. Law SL, Lo WY, Lin FM, Chaing CH. Dissolution and absorption of nifedipine in poly (ethylene glycol) solid dispersion containing phosphatidylcholine. Int J Pharm. 1992;84:161–166. doi: 10.1016/0378-5173(92)90056-8. [Cross Ref]
23. Doshi J, Reneker DH. Electrospinning process and applications of electrospun fibers. Paper presented at: Industry applications Society Annual Meeting, Toronto, Ontario, Canada, October 2–8, 1993. Conference Record of the 1993 IEEE. 1993;3:1698–1703.
24. Reneker DH, Chun I. Nanometre diameter fibres of polymer, produced by electrospinning. Nanotechnology. 1996;7:216–223. doi: 10.1088/0957-4484/7/3/009. [Cross Ref]
25. Ignatious F, Baldoni JM, inventors. Smithkline Beecham Corp. Electrospun pharmaceutical compositions. World patent 0 154 667. August 2, 2001.
26. Wnek GE, Kenawy ER, Bowlin GL, et al. Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinyl-acetate), poly (lactic acid) and a blend. J Control Release. 2002;81:57–64. doi: 10.1016/S0168-3659(02)00041-X. [PubMed] [Cross Ref]
27. Deitzel JM, Kleinmeyer J, Harris D, Beck Tan NC. The effect of processing variables on the morphology of electrospun nanofibers and textiles. Polym. 2001;42:261–272. doi: 10.1016/S0032-3861(00)00250-0. [Cross Ref]
28. Verreck G, Chun I, Peeters J, Rosenblatt J, Brewster ME. Preparation and characterization of nanofibers containing amorphous drug dispersions generated by electrostatic spinning. Pharm Res. 2003;20:810–817. doi: 10.1023/A:1023450006281. [PubMed] [Cross Ref]
29. Dennis AB, Farr SJ, Kellaway IW, Taylor G, Davidson R. In vivo evaluation of rapid release and sustained release Gelucire capsule formulations. Int J Pharm. 1990;65:85–100. doi: 10.1016/0378-5173(90)90013-T. [Cross Ref]
30. Pozzi F, Longo A, Lazzarini C, Carenzi A. Formulations of ubidecarenone with improved bioavailability. Eur J Pharm Biopharm. 1991;37:243–246.
31. Dordunoo SK, Ford JL, Rubinstein MH. Preformulation studies on solid dispersions containing triamterene or temazepam in polyethylene glycols or Gelucire 44/14 for liquid filling of hard gelatin capsules. Drug Dev Ind Pharm. 1991;17:1685–1713. doi: 10.3109/03639049109057315. [Cross Ref]
32. Sheen PC, Khetarpal VK, Cariola CM, Rowlings CE. Formulation studies of a poorly water-soluble drug in solid dispersions to improve bioavailability. Int J Pharm. 1995;118:221–227. doi: 10.1016/0378-5173(94)00366-D. [Cross Ref]
33. Porter CJH, Charman SA, Williams RD, Bakalova MV, Charman WN. Evaluation of emulsifiable glasses for the oral administration of cyclosporin in beagle dogs. Int J Pharm. 1996;141:227–237. doi: 10.1016/0378-5173(96)04641-8. [Cross Ref]
34. Aungst BJ, Nguyen NH, Rogers NJ, et al. Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses. Int J Pharm. 1997;156:79–88. doi: 10.1016/S0378-5173(97)00189-0. [Cross Ref]
35. Morris KR, Knipp GT, Serajuddin ATM. Structural properties of poly(ethylene glycol)-polysorbate 80 mixture, a solid dispersion vehicle. J Pharm Sci. 1992;81:1185–1188. doi: 10.1002/jps.2600811212. [PubMed] [Cross Ref]
36. Veiga MD, Escobar C, Bernard MJ. Dissolution behavior of drugs from binary and ternary systems. Int J Pharm. 1993;93:215–220. doi: 10.1016/0378-5173(93)90180-N. [Cross Ref]
37. Sjokvist E, Nystrom C, Alde'n M, Caram-Lelham N. Physicochemical aspects of drug release. XIV. The effects of some ionic and nonionic surfactants on properties of a sparingly soluble drug in solid dispersions. Int J Pharm. 1992;79:23–133. doi: 10.1016/0378-5173(92)90103-9. [Cross Ref]
38. Sheen PC, Kim SI, Petillo JJ, Serajuddin ATM. Bioavailability of a poorly water-soluble drug from tablet and solid dispersion in humans. J Pharm Sci. 1991;80:712–714. doi: 10.1002/jps.2600800722. [PubMed] [Cross Ref]
39. Gines JM, Veiga MD, Arias MJ, Rabasco AM. Elaboration and thermal study of interactions between cinnarizine and Gelucire 53/10 physical mixtures and solid dispersions. Int J Pharm. 1995;126:287–291. doi: 10.1016/0378-5173(95)04140-0. [Cross Ref]
40. Cole ET. Equipment for filling and sealing liquids in hard gelatin capsules. Bull Technique-Gattefosse. 1996;89:87–88.
41. Serajuddin ATM, Sheen PC, Augustine MA. Water migration from soft gelatin capsule shell to fill material and its effect on drug solubility. J Pharm Sci. 1986;75:62–64. doi: 10.1002/jps.2600750114. [PubMed] [Cross Ref]
42. Maes P, Brusselmans J, Sereno A, Pitti C, Sonck M, Coffiner M. In vitro and in vivo behavior of some liquid or semisolid filled hard gelatin capsules. Bull Technique-Gattefosse. 1996;89:63–69.
43. Al-Razzak LA, Dias L, Kaul D, Ghosh S. Lipid based systems for oral delivery: Physiological, mechanistic, and product development perspectives; Alexandria, VA: AAPS; 1997. pp. 18–18.
44. Phillips EM, Stella VJ. Rapid expansion from supercritical solutions: application to pharmaceutical processes. Int J Pharm. 1993;94:1–10. doi: 10.1016/0378-5173(93)90002-W. [Cross Ref]
45. Subramaniam B, Rajewski RA, Snavely K. Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci. 1997;86:885–890. doi: 10.1021/js9700661. [PubMed] [Cross Ref]
46. McHugh MA, Krukonis VJ. Supercritical Fluid Extraction: principles and Practice. Newton, MA: Butterworth-Heinmann; 1994.
47. Sunkara G, Kompella UB. Drug delivery applications of supercritical fluid technology. Drug Del Technol. 2002;2:44–50.
48. Beach S, Latham D, Sidgwick C, Hanna M, York P. Control of the physical form of salmeterol xinofoate. Org Proc Res Dev. 1993;3:370–376. doi: 10.1021/op990160z. [Cross Ref]
49. Kakumanu VK, Bansal AK. Supercritical fluid technology in pharmaceutical research. CRIPS. 2003;4:8–12.
50. Liu G-T, Nagahama K. Solubility and RESS experiments of solid solution in super critical carbon dioxide. J Chem Eng of Jpn. 1997;30:293–301. doi: 10.1252/jcej.30.293. [Cross Ref]
51. Hanna M, York P, inventors. University of Bradford. Method and apparatus for the formation of particles. World patent 9 501 221. January 12, 1995.
52. Juppo AM, Boiddier C, Khoo C. Evaluation of solid dispersion particles prepared with SEDS. Int J Pharm. 2003;250:385–401. doi: 10.1016/S0378-5173(02)00577-X. [PubMed] [Cross Ref]
53. York P, Wilkins SA, Storey RA, Walker SE, Harland RS, inventors. Bradford Particle Design PLC, Bristol-Myers Squibb. Coformulation methods and their products. World patent 0 115 664. March 8, 2001.
54. Sencar-Bozic P, Srcic S, Knez Z, Kere J. Improvement of nifedipine dissolution characteristics using supercritical CO2. Int J Pharm. 1997;148:123–130. doi: 10.1016/S0378-5173(96)04838-7. [Cross Ref]
55. Kerc J, Srcic S, Knez Z, Sencar-Bozic P. Micronization of drugs using supercritical carbon dioxide. Int J Pharm. 1999;182:33–39. doi: 10.1016/S0378-5173(99)00063-0. [PubMed] [Cross Ref]
56. Palakodaty S, York P. Phase behavioral effects on particle formation processes using supercritical fluids. Pharm Res. 1999;16:976–985. doi: 10.1023/A:1011957512347. [PubMed] [Cross Ref]
57. Gallagher PM, Coffey MP, Krukonis VJ, Klasuits N. Gas-antisolvent recrystallization: new process to recrystallize compounds insoluble in supercritical fluids. ACS Symp Ser. 1989;406:586–594.
58. Moneghini M, Kikic I, Voinovich D, Perissutti B, Filipovic-Greic J. Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterization, and in vitro dissolution. Int J Pharm. 2001;222:129–138. doi: 10.1016/S0378-5173(01)00711-6. [PubMed] [Cross Ref]
59. Sethia S, Squillante E. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method. J Pharm Sci. 2002;91:1948–1957. doi: 10.1002/jps.10186. [PubMed] [Cross Ref]
60. Berens AR, Huvard GS, Korsmeyer RW, Kunig RW. Application of compressed carbon dioxide in the incorporation of additives into polymers. J Appl Polym Sci. 1992;46:231–242. doi: 10.1002/app.1992.070460204. [Cross Ref]
61. Kazarian SG, Martirosyan GG. Spectroscopy of polymer/drug formulations processed with supercritical fluids: in situ ATR-IR and Raman study of impregnation of ibuprofen into PVP. Int J Pharm. 2002;232:81–90. doi: 10.1016/S0378-5173(01)00905-X. [PubMed] [Cross Ref]
62. Vincent MF, Kazarian SG, Eckert CA. Tunable diffusion of D2O in CO2-swollen poly (methylmethacrylate) films. AIChE J. 1997;43:1838–1848. doi: 10.1002/aic.690430719. [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists